Objective: to evaluate the effect of combined medication (human immunoglobulin+Yinzhihuang) in the treatment of neonatal ABO hemolytic jaundice. Methods: 100 newborns with ABO hemolytic jaundice treated in xian county...Objective: to evaluate the effect of combined medication (human immunoglobulin+Yinzhihuang) in the treatment of neonatal ABO hemolytic jaundice. Methods: 100 newborns with ABO hemolytic jaundice treated in xian county Hospital of Traditional Chinese Medicine from January 2020 to June 2022 were randomly divided into two groups. For the 50 children in the control group, only human immunoglobulin was used, while for the 50 children in the observation group, human immunoglobulin and Yinzhihuang were used. The treatment effect, symptom improvement, before and after treatment between groups were analyzed. Results: the total effective rate of the observation group was 96.00%, which was significantly higher than that of the control group (84.00%, P < 0.05). In the observation group, the time for jaundice to subside, the time for first defecation, and the time for stool to turn yellow were all shorter than those in the control group, and the daily defecation times were more than those in the control group (P < 0.05). Before treatment, there was no difference in total bilirubin (TBIL), direct bilirubin (DBIL) and indirect bilirubin (IBIL) levels between the two groups (P > 0.05). After treatment, the levels of TBIL, DBIL and IBIL in the observation group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of superoxide dismutase (SOD), malondialdehyde (MDA), CD4 and CD8 between the two groups (P > 0.05). After treatment, the levels of SOD, CD4 and CD8 in the observation group were higher than those in the control group, while the level of MDA was lower than that in the control group (P < 0.05). Before treatment, there was no difference between the two groups in behavioral ability, passive muscle tone, active muscle tone, original reflex and general evaluation (P > 0.05). After treatment, the scores of NBNA scale in the observation group were higher than those in the control group (P < 0.05). Conclusion: in the treatment of neonatal ABO hemolytic jaundice, the combination of human immunoglobulin and Yinzhihuang can achieve ideal results, and can better improve the serum bilirubin level, biochemical index level and neurobehavioral score, which is worthy of reference and application.展开更多
目的通过对南京市妇幼保健院ABO胎儿新生儿溶血病(hemolytic disease of the fetus and newborn,HDFN)发生情况进行回顾性调查分析,探讨ABO-HDFN患儿胆红素水平及血清学检测结果影响因素。方法选取2022年1月─2023年12月收治的1131例确...目的通过对南京市妇幼保健院ABO胎儿新生儿溶血病(hemolytic disease of the fetus and newborn,HDFN)发生情况进行回顾性调查分析,探讨ABO-HDFN患儿胆红素水平及血清学检测结果影响因素。方法选取2022年1月─2023年12月收治的1131例确诊为ABO-HDFN患儿作为研究对象,检测其血清总胆红素(total bilirubin,TBIL)、间接胆红素(indirect bilirubin,IBIL)、血红蛋白(hemoglobin,Hb)和碳氧血红蛋白(carboxyhemoglobin,COHb)水平,同时进行溶血三项血清学检测,并收集患儿体重、胎龄、就诊日龄等临床资料,分析患儿胆红素水平、溶血发生及其严重程度影响因素。结果1131例确诊为ABO溶血的患儿中,胎龄39.14(38,40.14)周,体重3240(2890,3540)克。TBIL和IBIL水平在出生体重、是否多胎、胎龄、分娩方式、喂养方式和就诊日龄方面差异有统计学意义(P<0.05);TBIL和IBIL水平在性别、血型和胎次方面差异无统计学意义(P>0.05)。三项血清学检测中直接抗球蛋白试验(direct antiglobulin test,DAT)阳性率19.36%(219/1131),游离抗体试验阳性率84.08%(951/1131),放散试验阳性率100%;将三项血清学结果分为“三项阳性”、“两项阳性”和“一项阳性”三组,患儿TBIL、IBIL、Hb和COHb水平在不同分组中差异有统计学意义(P<0.05)。日龄≤3 d患儿DAT、游离抗体试验的阳性率最高,分别为29.22%(161/551)、90.74%(500/551),日龄4~7 d患儿DAT、游离抗体试验的阳性率分别为11.31%(57/504)、79.96%(403/504),日龄≥8 d患儿DAT、游离抗体试验的阳性率分别为1.32%(1/76)、63.1%(48/76)。随着日龄的增加,患儿直抗、游离的阳性率也随之降低(P<0.001)。结论ABO-HDFN严重程度跟血清学三项试验、Hb和COHb有关;针对母婴ABO血型不合的患儿,应及时进行胆红素水平和三项血清学检测,对ABO-HDFN的预防和治疗有重要意义。展开更多
文摘Objective: to evaluate the effect of combined medication (human immunoglobulin+Yinzhihuang) in the treatment of neonatal ABO hemolytic jaundice. Methods: 100 newborns with ABO hemolytic jaundice treated in xian county Hospital of Traditional Chinese Medicine from January 2020 to June 2022 were randomly divided into two groups. For the 50 children in the control group, only human immunoglobulin was used, while for the 50 children in the observation group, human immunoglobulin and Yinzhihuang were used. The treatment effect, symptom improvement, before and after treatment between groups were analyzed. Results: the total effective rate of the observation group was 96.00%, which was significantly higher than that of the control group (84.00%, P < 0.05). In the observation group, the time for jaundice to subside, the time for first defecation, and the time for stool to turn yellow were all shorter than those in the control group, and the daily defecation times were more than those in the control group (P < 0.05). Before treatment, there was no difference in total bilirubin (TBIL), direct bilirubin (DBIL) and indirect bilirubin (IBIL) levels between the two groups (P > 0.05). After treatment, the levels of TBIL, DBIL and IBIL in the observation group were lower than those in the control group (P < 0.05). Before treatment, there was no difference in the levels of superoxide dismutase (SOD), malondialdehyde (MDA), CD4 and CD8 between the two groups (P > 0.05). After treatment, the levels of SOD, CD4 and CD8 in the observation group were higher than those in the control group, while the level of MDA was lower than that in the control group (P < 0.05). Before treatment, there was no difference between the two groups in behavioral ability, passive muscle tone, active muscle tone, original reflex and general evaluation (P > 0.05). After treatment, the scores of NBNA scale in the observation group were higher than those in the control group (P < 0.05). Conclusion: in the treatment of neonatal ABO hemolytic jaundice, the combination of human immunoglobulin and Yinzhihuang can achieve ideal results, and can better improve the serum bilirubin level, biochemical index level and neurobehavioral score, which is worthy of reference and application.
文摘目的通过对南京市妇幼保健院ABO胎儿新生儿溶血病(hemolytic disease of the fetus and newborn,HDFN)发生情况进行回顾性调查分析,探讨ABO-HDFN患儿胆红素水平及血清学检测结果影响因素。方法选取2022年1月─2023年12月收治的1131例确诊为ABO-HDFN患儿作为研究对象,检测其血清总胆红素(total bilirubin,TBIL)、间接胆红素(indirect bilirubin,IBIL)、血红蛋白(hemoglobin,Hb)和碳氧血红蛋白(carboxyhemoglobin,COHb)水平,同时进行溶血三项血清学检测,并收集患儿体重、胎龄、就诊日龄等临床资料,分析患儿胆红素水平、溶血发生及其严重程度影响因素。结果1131例确诊为ABO溶血的患儿中,胎龄39.14(38,40.14)周,体重3240(2890,3540)克。TBIL和IBIL水平在出生体重、是否多胎、胎龄、分娩方式、喂养方式和就诊日龄方面差异有统计学意义(P<0.05);TBIL和IBIL水平在性别、血型和胎次方面差异无统计学意义(P>0.05)。三项血清学检测中直接抗球蛋白试验(direct antiglobulin test,DAT)阳性率19.36%(219/1131),游离抗体试验阳性率84.08%(951/1131),放散试验阳性率100%;将三项血清学结果分为“三项阳性”、“两项阳性”和“一项阳性”三组,患儿TBIL、IBIL、Hb和COHb水平在不同分组中差异有统计学意义(P<0.05)。日龄≤3 d患儿DAT、游离抗体试验的阳性率最高,分别为29.22%(161/551)、90.74%(500/551),日龄4~7 d患儿DAT、游离抗体试验的阳性率分别为11.31%(57/504)、79.96%(403/504),日龄≥8 d患儿DAT、游离抗体试验的阳性率分别为1.32%(1/76)、63.1%(48/76)。随着日龄的增加,患儿直抗、游离的阳性率也随之降低(P<0.001)。结论ABO-HDFN严重程度跟血清学三项试验、Hb和COHb有关;针对母婴ABO血型不合的患儿,应及时进行胆红素水平和三项血清学检测,对ABO-HDFN的预防和治疗有重要意义。
